FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1574152642> ?p ?o ?g. }

• W1574152642 endingPage "2518" @default.
• W1574152642 startingPage "2512" @default.
• W1574152642 abstract "SummaryObjectives: To evaluate the clinical accuracy of antiphospholipid antibody (aPL) specificities both individually and/or in combination, in a wide cohort of systemic lupus erythematosus (SLE) patients in an attempt to identify a panel of tests that may provide the best accuracy for diagnosing antiphospholipid syndrome (APS). Patients and Methods: This study included 230 patients (218 women, mean age 42.7 ± 11.9 years, mean disease duration 12.2 ± 8.7 years), all fulfilling the 1982 criteria for SLE. All patients were tested for lupus anticoagulant (LA), anti‐cardiolipin (aCL), anti‐β2glycoprotein I (anti‐β2GPI), solid phase anti‐prothrombin (aPT), anti‐phosphatidylserine/prothrombin (aPS/PT), and anti‐phosphatidylethanolamine (aPE) antibodies. Sensitivity, specificity and predictive values were calculated. The diagnostic accuracy for each combination of tests was assessed by ROC and their area under the curve analysis as well as by the Youden’s index (YI). Results: Testing for six aPL derived 23 possible combinations of results. Among them, LA + anti‐β2GPI + aPS/PT had the best diagnostic accuracy for APS as a whole and individually for both thrombosis and pregnancy loss (AUC 0.712, OR 3.73 [95% CI 1.82–5.38], P = 0.0001, YI = 0.32 and AUC 0.709, OR 3.75 [95% CI 2.13–6.62], P = 0.0001, YI = 0.37 and AUC 0.677, OR 4.82 [95% CI 2.17–10.72], P = 0.0007, YI = 0.38, respectively) and the best specificity when compared with all the other obtainable combination of tests. Triple positivity for LA + anti‐β2GPI + aPS/PT was more strongly associated with clinical events (thrombosis and/or PL) when compared with double or single positivity (OR 23.2 [95% CI 2.57–46.2] vs. OR 7.3 [95% CI 2.21–25.97], OR 5.7 [95% CI 2.12–17.01] or OR 3.11 [95% CI 1.56–7.8] for single positivity for LA, aPS/PT and anti‐β2GPI, respectively). Conclusions: Combining LA, anti‐β2GPI and aPS/PT improves the diagnostic power and helps in stratifying the risk for each patient, according to their aPL profile. Objectives: To evaluate the clinical accuracy of antiphospholipid antibody (aPL) specificities both individually and/or in combination, in a wide cohort of systemic lupus erythematosus (SLE) patients in an attempt to identify a panel of tests that may provide the best accuracy for diagnosing antiphospholipid syndrome (APS). Patients and Methods: This study included 230 patients (218 women, mean age 42.7 ± 11.9 years, mean disease duration 12.2 ± 8.7 years), all fulfilling the 1982 criteria for SLE. All patients were tested for lupus anticoagulant (LA), anti‐cardiolipin (aCL), anti‐β2glycoprotein I (anti‐β2GPI), solid phase anti‐prothrombin (aPT), anti‐phosphatidylserine/prothrombin (aPS/PT), and anti‐phosphatidylethanolamine (aPE) antibodies. Sensitivity, specificity and predictive values were calculated. The diagnostic accuracy for each combination of tests was assessed by ROC and their area under the curve analysis as well as by the Youden’s index (YI). Results: Testing for six aPL derived 23 possible combinations of results. Among them, LA + anti‐β2GPI + aPS/PT had the best diagnostic accuracy for APS as a whole and individually for both thrombosis and pregnancy loss (AUC 0.712, OR 3.73 [95% CI 1.82–5.38], P = 0.0001, YI = 0.32 and AUC 0.709, OR 3.75 [95% CI 2.13–6.62], P = 0.0001, YI = 0.37 and AUC 0.677, OR 4.82 [95% CI 2.17–10.72], P = 0.0007, YI = 0.38, respectively) and the best specificity when compared with all the other obtainable combination of tests. Triple positivity for LA + anti‐β2GPI + aPS/PT was more strongly associated with clinical events (thrombosis and/or PL) when compared with double or single positivity (OR 23.2 [95% CI 2.57–46.2] vs. OR 7.3 [95% CI 2.21–25.97], OR 5.7 [95% CI 2.12–17.01] or OR 3.11 [95% CI 1.56–7.8] for single positivity for LA, aPS/PT and anti‐β2GPI, respectively). Conclusions: Combining LA, anti‐β2GPI and aPS/PT improves the diagnostic power and helps in stratifying the risk for each patient, according to their aPL profile." @default.
• W1574152642 created "2016-06-24" @default.
• W1574152642 creator A5012705049 @default.
• W1574152642 creator A5017039749 @default.
• W1574152642 creator A5019968414 @default.
• W1574152642 creator A5043181396 @default.
• W1574152642 creator A5046145094 @default.
• W1574152642 creator A5071375228 @default.
• W1574152642 date "2012-12-01" @default.
• W1574152642 modified "2023-10-18" @default.
• W1574152642 title "Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities" @default.
• W1574152642 cites W1975074770 @default.
• W1574152642 cites W1991721757 @default.
• W1574152642 cites W1992631495 @default.
• W1574152642 cites W1993363490 @default.
• W1574152642 cites W2001800559 @default.
• W1574152642 cites W2032247921 @default.
• W1574152642 cites W2040170610 @default.
• W1574152642 cites W2041919675 @default.
• W1574152642 cites W2054330426 @default.
• W1574152642 cites W2061394912 @default.
• W1574152642 cites W2069797332 @default.
• W1574152642 cites W2097487666 @default.
• W1574152642 cites W2109203796 @default.
• W1574152642 cites W2119266650 @default.
• W1574152642 cites W2137733964 @default.
• W1574152642 cites W2140168373 @default.
• W1574152642 cites W2146203649 @default.
• W1574152642 cites W2149675904 @default.
• W1574152642 cites W4233681098 @default.
• W1574152642 cites W93524816 @default.
• W1574152642 doi "https://doi.org/10.1111/jth.12014" @default.
• W1574152642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23025466" @default.
• W1574152642 hasPublicationYear "2012" @default.
• W1574152642 type Work @default.
• W1574152642 sameAs 1574152642 @default.
• W1574152642 citedByCount "87" @default.
• W1574152642 countsByYear W15741526422013 @default.
• W1574152642 countsByYear W15741526422014 @default.
• W1574152642 countsByYear W15741526422015 @default.
• W1574152642 countsByYear W15741526422016 @default.
• W1574152642 countsByYear W15741526422017 @default.
• W1574152642 countsByYear W15741526422018 @default.
• W1574152642 countsByYear W15741526422019 @default.
• W1574152642 countsByYear W15741526422020 @default.
• W1574152642 countsByYear W15741526422021 @default.
• W1574152642 countsByYear W15741526422022 @default.
• W1574152642 countsByYear W15741526422023 @default.
• W1574152642 crossrefType "journal-article" @default.
• W1574152642 hasAuthorship W1574152642A5012705049 @default.
• W1574152642 hasAuthorship W1574152642A5017039749 @default.
• W1574152642 hasAuthorship W1574152642A5019968414 @default.
• W1574152642 hasAuthorship W1574152642A5043181396 @default.
• W1574152642 hasAuthorship W1574152642A5046145094 @default.
• W1574152642 hasAuthorship W1574152642A5071375228 @default.
• W1574152642 hasBestOaLocation W15741526421 @default.
• W1574152642 hasConcept C126322002 @default.
• W1574152642 hasConcept C159654299 @default.
• W1574152642 hasConcept C203014093 @default.
• W1574152642 hasConcept C2776874634 @default.
• W1574152642 hasConcept C2776912625 @default.
• W1574152642 hasConcept C2779134260 @default.
• W1574152642 hasConcept C2780022809 @default.
• W1574152642 hasConcept C2780868729 @default.
• W1574152642 hasConcept C43346845 @default.
• W1574152642 hasConcept C58471807 @default.
• W1574152642 hasConcept C71924100 @default.
• W1574152642 hasConcept C76318530 @default.
• W1574152642 hasConcept C90924648 @default.
• W1574152642 hasConceptScore W1574152642C126322002 @default.
• W1574152642 hasConceptScore W1574152642C159654299 @default.
• W1574152642 hasConceptScore W1574152642C203014093 @default.
• W1574152642 hasConceptScore W1574152642C2776874634 @default.
• W1574152642 hasConceptScore W1574152642C2776912625 @default.
• W1574152642 hasConceptScore W1574152642C2779134260 @default.
• W1574152642 hasConceptScore W1574152642C2780022809 @default.
• W1574152642 hasConceptScore W1574152642C2780868729 @default.
• W1574152642 hasConceptScore W1574152642C43346845 @default.
• W1574152642 hasConceptScore W1574152642C58471807 @default.
• W1574152642 hasConceptScore W1574152642C71924100 @default.
• W1574152642 hasConceptScore W1574152642C76318530 @default.
• W1574152642 hasConceptScore W1574152642C90924648 @default.
• W1574152642 hasIssue "12" @default.
• W1574152642 hasLocation W15741526421 @default.
• W1574152642 hasLocation W15741526422 @default.
• W1574152642 hasLocation W15741526423 @default.
• W1574152642 hasOpenAccess W1574152642 @default.
• W1574152642 hasPrimaryLocation W15741526421 @default.
• W1574152642 hasRelatedWork W2038468561 @default.
• W1574152642 hasRelatedWork W2081564697 @default.
• W1574152642 hasRelatedWork W2091684655 @default.
• W1574152642 hasRelatedWork W2264220786 @default.
• W1574152642 hasRelatedWork W2401447830 @default.
• W1574152642 hasRelatedWork W2415342018 @default.
• W1574152642 hasRelatedWork W2416230108 @default.
• W1574152642 hasRelatedWork W3043497346 @default.
• W1574152642 hasRelatedWork W4247855055 @default.
• W1574152642 hasRelatedWork W4308440492 @default.

• next